catadegbrutinib (BGB-16673) / BeOne Medicines - LARVOL DELTA

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation (ICML 2025) - P=N/A, P2, P3 | "BRUIN CLL-321 is a phase 3, registrational study that evaluated pirtobrutinib compared to the investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) [23]...Nemtabrutinib is now being evaluated in the registrational, phase 3 BELLWAVE-010 trial (NCT05947851) for patients with R/R CLL, comparing nemtabrutinib plus venetoclax to venetoclax plus rituximab...An ongoing, open-label, first-in-human phase 1/2 study is evaluating the BTK degrader BGB-16673 as monotherapy in patients with R/R CLL [27, 28]...NX-2127 is an investigational, first-in-class BTK degrader currently being evaluated in a phase 1 trial for patients with relapsed or refractory B-cell malignancies, CLL [29, 30]...NX-5948 is another investigational and more selective BTK degrader in an ongoing Phase 1a/1b clinical trial...This trial aims to establish lisaftoclax plus acalabrutinib as a potential alternative to venetoclax-based BTKi combination..."

IO biomarker • Acute Myelogenous Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • BCL2L1 • TP53

BGB-16673 (BTK degrader) clinical data demonstrates rapid, robust and deepening responses in patients with heavily pretreated R/R CLL/SLL, including those with prior BTKi treatment and mutations that confer resistance to BTK inhibitors. (Businesswire) - "With a median follow-up of 19.8 months, 54.4% of patients remain on treatment. Across all doses, ORR was 85.3% and CR/CR with incomplete count recovery (CRi) rate was 2.9% with responses deepening over time. In the group of patients dosed at the recommended phase 2 dose (RP2D; 200 mg QD), ORR was 94.4%. In the patients with prior covalent BTK inhibitor, BCL2i, and noncovalent BTK inhibitor treatment, ORR was 75.0%."

P1/2 data • Chronic Lymphocytic Leukemia • Small Lymphocytic Lymphoma

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor (ASH 2025) - P1/2, P3 | "Secondary endpoints include overall survival, PFS in patients with prior exposure to noncovalent BTK inhibitors by IRC, PFS by INV, overall response rate by IRC and INV, rate of partial response with lymphocytosis or higher by IRC and INV, duration of response by IRC and INV, time to next treatment, and safety/tolerability per National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Recruitment is ongoing."

Clinical • IO biomarker • P3 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Prolymphocytic Leukemia • Richter's Syndrome • Small Lymphocytic Lymphoma

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies (ASH 2025) - P1/2 | "Thecurrent master protocol includes four substudies with their prioritized histologies evaluating BGB-16673in combination with: sonrotoclax (substudy 1: CLL/SLL, WM, MCL, and MZL), zanubrutinib (substudy 2:CLL/SLL, WM, MCL, and MZL), mosunetuzumab (substudy 3: FL and CLL/SLL), and glofitamab (substudy 4:non-GCB DLBCL and MCL). In addition, several exploratoryanalyses to assess predictive, prognostic, and pharmacodynamic biomarkers may be performed usingpatient samples. Recruitment is ongoing."

Clinical • Combination therapy • P1/2 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia • BTK

Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation (ASH 2025) - P1 | "BTK A428D was detected at baseline but not at progression in a second patient.To evaluate the impact of BTK A428D on drug response, we transduced BTK-dependent TMD8 cells withBTK WT, C481S, L528W, and A428D, and found that BTK A428D uniquely conferred resistance to all FDA-approved BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib) as well as three BTKdegraders under clinical evaluation (zelebrudomide, bexobrutideg, BGB-16673). Combining the BTK degraders with venetoclax slowedthe emergence of the BTK A428D resistant population and, in the case of zelebrudomide, eradicated boththe wild-type and A428D clones.In summary, we identified and validated BTK A428D as a clinically relevant acquired pan-resistancemutation that confers resistance by blocking access to the ATP binding pocket. This mechanism differsfrom other kinase dead BTK mutations in which the kinase's enzymatic pocket remained accessible.Thesedata also provide rationale for combining..."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CRBN • SF3B1 • TP53

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas. (ASH 2025) - "Sensitivity to cBTK-i (zanubrutinib); ncBTK-i (pirtobrutinib); BTK PROTACs (BGB-16673, NX-2127, NX-5948); and a novel oral compound (DFCI-002-06)developed and characterized by us (Liu et al, Blood 2024; 144 Supp1: 834) that degrades HCK,LYN, and BTK were evaluated using CellTiter-Glo and apoptosis assays. Engineered TMD8 and BCWM.1 lines expressing various BTK mutations showedexpected resistance profiles: C481S conferred resistance to covalent BTKi, while all othermutations conferred resistance to pirtobrutinib. Our findings showed diverse signaling and vulnerabilities that accompany distinctBTK mutations associated with clinical resistance to covalent, non-covalent and PROTACstargeting BTK. We identified HCK and LYN dependent alternative pro-survival signaling in V416L,A428D, and L528W BTK mutant expressing cells which were deficient for BTK Y223 kinasesignaling. Importantly, we observed that the DFCI-002-06 which degrades HCK, LYN and BTKbroadly overcame..."

Clinical • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Targeted Protein Degradation • Waldenstrom Macroglobulinemia • BTK • HCK • LYN • MYD88 • NFKBIA • PLCG2 • STAT3

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study (ASH 2025) - P1/2 | "Data from the ongoing CaDAnCe-101 study demonstrate that the novel BTK degrader BGB-16673 has a tolerable safety profile and shows robust and deepening responses in patients with heavilypretreated R/R CLL/SLL, including those with prior BTK inhibitor treatment and BTK mutations. The 200-mg dose of BGB-16673 is being evaluated in phase 2 and 3 studies in patients with R/R CLL/SLL."

Clinical • P1 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma • Thrombocytopenia • BTK • IGH • PLCG2 • TP53

Never-before-presented clinical data from BeOne’s emerging pipeline will also be shared at the meeting, including in new combinations and disease areas. (Businesswire) - "BGB-11417-202: Phase 2 study of sonrotoclax monotherapy in patients with R/R CLL/SLL (Poster Presentation: 5666); BGB-11417-105: Initial results from Phase 1b/2 study of sonrotoclax plus carfilzomib and dexamethasone in patients with t(11;14)-positive R/R multiple myeloma (Oral Presentation: 102); CaDAnCe-101 Preliminary results from the ongoing Phase 1 study of BGB-16673 in patients with R/R Richter’s transformation (Poster Presentation: 3895)."

Clinical data • Chronic Lymphocytic Leukemia • Multiple Myeloma • Richter's Syndrome

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study (ASH 2025) - P1/2 | "Data from this ongoing phase 1 study demonstrate that the novel BTK degrader BGB-16673was well tolerated and continued to show substantial antitumor activity in patients with heavilypretreated BTK inhibitor–exposed R/R WM, including those with BTK, MYD88, CXCR4, and TP53mutations. Enrollment is ongoing in the phase 2 portion of the study."

Clinical • IO biomarker • P1 data • Atrial Fibrillation • Cardiovascular • Febrile Neutropenia • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Neutropenia • Respiratory Diseases • Septic Shock • Thrombocytopenia • Waldenstrom Macroglobulinemia • BTK • CXCR4 • MYD88 • PLCG2 • TP53

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study (ASH 2025) - P1/2 | "Data from this ongoing study demonstrate that the BTK degrader BGB-16673 has atolerable safety profile and a promising ORR of 52.4%, with evidence of responses lasting >6 months inheavily pretreated patients with R/R RT."

Clinical • IO biomarker • P1 data • Atrial Fibrillation • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Disorders • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • Richter's Syndrome • Small Lymphocytic Lymphoma • BTK • IGH • PLCG2 • TP53

Key presentations include (Businesswire) - "ALPINE: Post-hoc analysis from Phase 3 study of BRUKINSA versus ibrutinib in patients with relapsed/refractory (R/R) CLL/SLL, using longitudinal patient-reported outcomes (PRO) (Oral Presentation: 711); BGB-11417-201: Phase 1/2 study of sonrotoclax in patients with R/R mantle cell lymphoma (MCL) previously treated with a BTK inhibitor (Oral Presentation: 663); BGB-11417-101: Updated safety and efficacy results, including undetectable minimal residual disease (uMRD) data, from ongoing Phase 1/1b study of sonrotoclax plus BRUKINSA in treatment-naïve CLL/SLL (Poster Presentation: 3891); CaDAnCe-101: Updated efficacy and safety results of BGB-16673 in patients with R/R CLL/SLL and R/R Waldenström macroglobulinemia (WM) (Oral Presentation: 85; Poster Presentation: 3583)."

Clinical data • Chronic Lymphocytic Leukemia • Mantle Cell Lymphoma • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (ASH 2025) - P1/2, P3 | "Pirtobrutinib, a noncovalent BTK inhibitor,was recently approved for patients who relapsed following covalent BTK inhibitor therapy such asibrutinib, acalabrutinib, or zanubrutinib. Secondary endpoints include overall survival, PFS by investigator (INV),overall response rate by IRC and INV, rate of partial response with lymphocytosis or higher by IRC andINV, duration of response by IRC and INV, time to next treatment, safety/tolerability per NCI CTCAE v5.0,and patient-reported outcomes. This study is actively recruiting."

Clinical • IO biomarker • P3 data • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Prolymphocytic Leukemia • Richter's Syndrome • Small Lymphocytic Lymphoma • BTK

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study (ASH 2025) - P1/2 | "These data demonstrate that the novel BTK degrader BGB-16673 is tolerable and showsclinically beneficial responses in heavily pretreated patients with FL and, particularly, MZL, includingthose who received a prior BTK inhibitor. CaDAnCe-101 enrollment continues for patients with FL andMZL."

Clinical • P1 data • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Febrile Neutropenia • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Respiratory Diseases • BTK

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101) (ASH 2023) - P1/2 | "Preliminary data from this ongoing, first-in-human study of the novel BTK degrader BGB-16673 demonstrate a tolerable safety profile and clinical responses in heavily pretreated pts with B-cell malignancies, including those with BTKi-resistant disease. Substantial reductions in BTK protein levels in peripheral blood and tumor tissue were also observed, demonstrating proof-of-concept of a strong, on-target effect."

Clinical • First-in-human • IO biomarker • P1 data • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Musculoskeletal Pain • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Septic Shock • Solid Tumor • Targeted Protein Degradation • Urothelial Cancer • Waldenstrom Macroglobulinemia • BTK • IGH • TP53

Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants (clinicaltrials.gov) - P1 | N=37 | Completed | Sponsor: BeiGene | Recruiting ➔ Completed

Trial completion

Bgb-16673, a Selective BTK Degrader, Exhibits Deeper Inhibition of Cancer Cell Signaling Pathways and Better Efficacy in MCL Models (ASH 2024) - P1/2 | "Over the past decade, the development and approval of covalent BTK inhibitors (cBTKis) like ibrutinib, acalabrutinib, and zanubrutinib, as well as the non-covalent BTK inhibitor (ncBTKi) pirtobrutinib, have marked substantial progress of targeting BTK in MCL. Results also support the combination of BGB-16673 with Bcl-2 inhibitors in MCL. These discoveries highlight the potential of BGB-16673 in treating MCL patients."

Clinical • IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study (ASH 2024) - P1/2 | "Responses were seen in patients previously treated with a cBTKi (2/4 in MZL and 0/1 in FL with prior cBTKi) and a ncBTKi (0/1 in MZL and 1/1 in FL with prior ncBTKi). Conclusions : Emerging data from this ongoing, first-in-human study demonstrate that the novel BTK degrader BGB-16673 has a tolerable safety profile and shows clinically meaningful, durable responses in heavily pretreated patients with FL and MZL, including those with prior BTK inhibitor treatment."

Clinical • IO biomarker • P1 data • Atrial Fibrillation • Cardiovascular • Fatigue • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hypertension • Indolent Lymphoma • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • Targeted Protein Degradation • BTK

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study (ASH 2024) - P1/2 | "One patient had IgM flare at initial response assessment and went on to develop PR. Conclusions : Early data from this ongoing, first-in-human study demonstrate that the novel BTK degrader BGB-16673 has a tolerable safety profile and shows promising antitumor activity in heavily pretreated patients with BTK inhibitor–exposed R/R WM, including those with BTK and CXCR4 mutations."

Clinical • IO biomarker • P1 data • Atrial Fibrillation • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Neutropenia • Oncology • Otorhinolaryngology • Respiratory Diseases • Septic Shock • Sinusitis • Targeted Protein Degradation • Waldenstrom Macroglobulinemia • BTK • CXCR4 • MYD88

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study (ASH 2024) - P1/2 | "Responses were seen at the lowest dose, as well as in patients previously treated with a cBTKi, ncBTKi, double- (cBTKi and BCL2i) and triple- (cBTKi, BCL2i, ncBTKi) exposed patients, and in patients with and without BTK mutations. Conclusions : Emerging data from this ongoing, first-in-human study demonstrate that the novel BTK degrader BGB-16673 has a tolerable safety profile and shows promising and deep overall responses in heavily pretreated patients with R/R CLL/SLL, including those with prior BTK inhibitor treatment and BTK resistance mutations."

Clinical • IO biomarker • P1 data • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Fatigue • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Small Lymphocytic Lymphoma • Targeted Protein Degradation • BTK • IGH • TP53

Updated Efficacy/Safety of the Bruton Tyrosine Kinase (BTK) Degrader BGB-16673 in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Ongoing Phase (Ph) 1 CaDAnCe-101 Study (DGHO 2025) - P1/2 | "Novel BTK degrader BGB-16673 is tolerable, with robust and deepening responses in pts with heavily pretreated R/R CLL/SLL, including pts with prior BTKis and BTKi mutations."

Clinical • IO biomarker • Atrial Fibrillation • Cardiovascular • Chronic Lymphocytic Leukemia • Fatigue • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • BTK • IGH • TP53

Updated Efficacy & Safety of the Bruton Tyrosine Kinase (BTK) Degrader BGB-16673 in Patients (Pts) With Relapsed/Refractory (R/R) Waldenström Macroglobulinemia (WM): Ongoing Phase (Ph) 1 CaDAnCe-101 Study Results (DGHO 2025) - P1/2 | "Novel BTK degrader BGB-16673 is tolerable with substantial antitumor activity in pts with heavily pretreated, BTKi–exposed WM, including those with BTK, CXCR4, and TP53 mutations. ​"

Clinical • IO biomarker • Anemia • Atrial Fibrillation • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Hypertension • Lymphoma • Lymphoplasmacytic Lymphoma • Neutropenia • Thrombocytopenia • Waldenstrom Macroglobulinemia • BTK • CXCR4 • MYD88 • TP53

MODULE 4: Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL (ASH 2025) - "This program is supported by educational grants from Abbvie Inc., AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, and Eli Lilly. Published efficacy and safety findings with lisocabtagene maraleucel (liso-cel) for R/R CLL from the Phase I/II TRANSCEND CLL 004 trial FDA approval of liso-cel for CLL previously treated with a BTK inhibitor and a Bcl-2 inhibitor; current clinical role and optimal patient selection Early findings with other CAR T-cell-based approaches, such as liso-cel in combination with ibrutinib, for heavily pretreated CLL Biological rationale for the investigation of bispecific antibodies for patients with R/R CLL Antitumor activity and safety documented with epcoritamab for R/R CLL and CLL with Richter's syndrome in the Phase Ib/II EPCORE CLL-1 study Mechanistic similarities and differences between BTK degraders and BTK inhibitors; implications for the efficacy of these strategies for patients with BTK resistance mutations Updated safety..."

CAR T-Cell Therapy • IO biomarker • Chronic Lymphocytic Leukemia • Richter's Syndrome

BTK-EndoMut Platform: Engineered Resistance Models Accelerating BTK-Targeted Drug Discovery (AACR-NCI-EORTC 2025) - "Mutant TMD8 lines display broad IC50 shifts: A428D and L528W confer >100-fold resistance to both ibrutinib and pirtobrutinib, C481S remains nanomolar to pirtobrutinib, whereas T474I/V416L stay responsive to zanubrutinib; all variants expect A428D retain low-nanomolar BGB-16673 and NX-5948 susceptibility. In vivo, C481F tumors show modest ibrutinib delay, whereas L528W xenografts resist ibrutinib yet regress under daily NX-5948 without overt weight loss. Proliferation assays mirror these drug-response patterns across the panel.Impact: Kyinno's BTK-mutant lines accelerate high-throughput screening of small-molecule inhibitors and targeted degraders, delineate resistance circuitry via isogenic comparisons, and improve translational relevance by faithfully modeling patient-derived escape variants."

Oncology • BTK

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report. (PubMed, Cureus) - "We present a case of invasive cutaneous mucormycosis in an elderly man with chronic lymphocytic leukemia (CLL), who was receiving a Bruton tyrosine kinase (BTK)-targeted protein degrader trial drug (BGB-16673), obinutuzumab, a newer anti-CD20 monoclonal therapy, and idelalisib, a phosphoinositide 3-kinase inhibitor. Clinical cure was achieved with limb amputation, given the extent of disease. This case underscores the necessity of a low index of suspicion for mucormycosis on presentation, critical appraisal of the patient's risk factors, and a multimodal approach to diagnosis."

Journal • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • BTK

UPDATED EFFICACY & SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB-16673 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) WALDENSTRÖM MACROGLOBULINEMIA (WM): ONGOING PHASE (PH) 1 CADANCE-101 STUDY RESULTS (SIE 2025) - P1/2 | "Conclusions. In this ongoing study, the novel BTK degrader BGB-16673 is tolerable and continues to show substantial antitumor activity in pts with heavily pretreated, BTKi–exposed WM, including those with BTK, CXCR4, and TP53 mutations."

Clinical • IO biomarker • Anemia • Atrial Fibrillation • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Hypertension • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Neutropenia • Thrombocytopenia • Waldenstrom Macroglobulinemia • BTK • CXCR4 • MYD88 • TP53